Drug
GS-9669 clinical trials
Also written GS-9669.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Development codes
- GS-9669
- 3
Studies by the year they started
4 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 1
Gilead Sciences (3) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Often tested with
Tested in the same studies.
Ribavirin (2) · Ledipasvir, sofosbuvir drug combination (1) · Sofosbuvir (1) · Interferons (1) · Velpatasvir (1) · GS-9451 (1)
Studies
Open first, then newest update. How each study uses GS-9669 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV InfectionCompletedPhase 2Gilead SciencesNCT01984294Written as GS-9669
- Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV InfectionCompletedPhase 2Gilead SciencesNCT01826981Written as GS-9669
- Combination Therapy for Chronic Hepatitis C InfectionCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01805882Written as GS-9669
- Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus InfectionCompletedPhase 1Gilead SciencesNCT01431898Written as GS-9669 tablets